ABBV-324
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ABBV-324, covering 2026-03-25 to 2026-03-25. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) [Phase 1]